Uwe Rix
Impact in
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 10
- Protein Degradation and Inhibitors 8
- Oncology 28
- Cancer-related Molecular Pathways 7
- Co-authors
- Giulio Superti‐Furga (32 shared papers)Lily L. Remsing Rix (26 shared papers)Oliver Hantschel (6 shared papers)Keiryn L. Bennett (21 shared papers)Jürgen Rohr (13 shared papers)Jacques Colinge (18 shared papers)Peter Valent (15 shared papers)Eric B. Haura (33 shared papers)
- Journals
- Blood (8 papers)Cancer Research (6 papers)Molecular Cancer Therapeutics (6 papers)Nature Chemical Biology (5 papers)ACS Chemical Biology (4 papers)
- Partner nations
- United StatesAustriaGermany
In The Last Decade
Uwe Rix
93 papers receiving 5.0k citations
Uwe Rix's Hit Papers
Peers
Comparison fields: 5 of 111
- Hematology 922
- Genetics 681
- Pharmacology 870
- Oncology 996
- Toxicology 126
Countries citing papers authored by Uwe Rix
This map shows the geographic impact of Uwe Rix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Rix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Rix more than expected).
Fields of papers citing papers by Uwe Rix
This network shows the impact of papers produced by Uwe Rix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Rix. The network helps show where Uwe Rix may publish in the future.
Co-authors
The 25 scholars most cited alongside Uwe Rix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 95 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Hit paper breakdown → | 2007 | 552 |
| 2 | Target profiling of small molecules by chemical proteomics Hit paper breakdown → | 2008 | 490 |
| 3 | 2007 | 244 | |
| 4 | 2008 | 232 | |
| 5 | 2002 | 226 | |
| 6 | 2010 | 223 | |
| 7 | 2008 | 206 | |
| 8 | 2019 | 124 | |
| 9 | 2003 | 120 | |
| 10 | 2017 | 110 | |
| 11 | 2011 | 96 | |
| 12 | 2013 | 92 | |
| 13 | 2012 | 84 | |
| 14 | 2009 | 79 | |
| 15 | 2004 | 79 | |
| 16 | 2000 | 78 | |
| 17 | 2016 | 78 | |
| 18 | 2008 | 75 | |
| 19 | 2013 | 75 | |
| 20 | 2005 | 73 |
About Uwe Rix
Uwe Rix is a scholar working on Molecular Biology, Oncology, Hematology, Genetics and Organic Chemistry, having authored 95 papers that have together received 5.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (17 papers), Chronic Lymphocytic Leukemia Research (15 papers), Microbial Natural Products and Biosynthesis (12 papers), Advanced Proteomics Techniques and Applications (11 papers), Lung Cancer Treatments and Mutations (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Protein Degradation and Inhibitors (8 papers) and Cancer-related Molecular Pathways (7 papers). The work is most often cited by research in Hematology (922 citations), Genetics (681 citations), Pharmacology (870 citations), Oncology (996 citations) and Toxicology (126 citations). Uwe Rix has collaborated with scholars based in United States, Austria and Germany. Frequent co-authors include Giulio Superti‐Furga, Lily L. Remsing Rix, Oliver Hantschel, Keiryn L. Bennett, Jürgen Rohr, Jacques Colinge, Peter Valent, Eric B. Haura, Lily L. Remsing and John M. Koomen. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, Nature Chemical Biology and ACS Chemical Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.